We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-29.4%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$106M
AUM Growth
-$49.2M
Cap. Flow
+$4.09M
Cap. Flow %
3.87%
Top 10 Hldgs %
82.96%
Holding
60
New
6
Increased
11
Reduced
8
Closed
8

Top Buys

Rank Stock Value
1
EQM
EQM Midstream Partners, LP
EQM
+$2.38M
2
CELG
Celgene Corp
CELG
+$2.13M
3
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$1.24M
4
QDEL icon
QuidelOrtho
QDEL
+$782K
5
NBIX icon
Neurocrine Biosciences
NBIX
+$671K

Top Sells

Rank Stock Value
1
CFRX
ContraFect Corporation
CFRX
+$1.1M
2
EQT icon
EQT Corp
EQT
+$938K
3
OVV icon
Ovintiv
OVV
+$629K
4
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$397K
5
AXGN icon
Axogen
AXGN
+$369K

Sector Composition

Rank Sector Weight
1 Healthcare 95.72%
2 Energy 3.02%
3 Materials 0.13%
4 Industrials 0.12%
5 Consumer Staples 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$44.8M 42.38%
699,011
+28,830
+4% +$2.13M
AXDX
2
DELISTED
Accelerate Diagnostics
AXDX
$25.1M 23.76%
218,380
– –
NBIX icon
3
Neurocrine Biosciences
NBIX
$17.2B
$3.93M 3.72%
55,000
+7,000
+15% +$671K
CMTA
4
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$2.61M 2.47%
222,000
+100,000
+82% +$1.24M
ARRY
5
DELISTED
Array Biopharma Inc
ARRY
$2.39M 2.26%
168,000
+40,000
+31% +$607K
QDEL icon
6
QuidelOrtho
QDEL
$1.19B
$2.3M 2.17%
47,075
+13,100
+39% +$782K
EQM
7
DELISTED
EQM Midstream Partners, LP
EQM
$2.16M 2.05%
+50,000
New +$2.38M
VNDA icon
8
Vanda Pharmaceuticals
VNDA
$327M
$2.09M 1.98%
80,000
-8,000
-9% -$188K
ATRA icon
9
Atara Biotherapeutics
ATRA
$75.6M
$1.18M 1.12%
1,360
– –
SLNO
10
DELISTED
Soleno Therapeutics
SLNO
$1.12M 1.06%
43,773
– –
OXFD
11
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$1.03M 0.97%
80,303
-20,000
-20% -$303K
HROW icon
12
Harrow
HROW
$1.74B
$1.02M 0.97%
180,000
– –
ALBO
13
DELISTED
Albireo Pharma Inc
ALBO
$932K 0.88%
38,000
– –
MASI
14
DELISTED
Masimo
MASI
$859K 0.81%
8,000
– –
ARNA
15
DELISTED
Arena Pharmaceuticals Inc
ARNA
$857K 0.81%
22,000
– –
WMGI
16
DELISTED
Wright Medical Group Inc
WMGI
$817K 0.77%
30,000
– –
XLRN
17
DELISTED
Acceleron Pharma
XLRN
$813K 0.77%
18,672
+6,672
+56% +$333K
BIIB icon
18
Biogen
BIIB
$30.4B
$752K 0.71%
2,500
+500
+25% +$160K
CORT icon
19
Corcept Therapeutics
CORT
$9.72B
$668K 0.63%
50,000
– –
KPTI icon
20
Karyopharm Therapeutics
KPTI
$216M
$656K 0.62%
4,667
+1,334
+40% +$225K
VRML
21
DELISTED
Vermillion, Inc.
VRML
$634K 0.6%
2,113,933
-119,000
-5% -$60.7K
VCYT icon
22
Veracyte
VCYT
$4.72B
$613K 0.58%
48,767
– –
IFRX icon
23
InflaRx
IFRX
$272M
$582K 0.55%
16,000
– –
AMRN
24
Amarin Corp
AMRN
$292M
$544K 0.51%
2,000
– –
SIEN
25
DELISTED
Sientra, Inc.
SIEN
$508K 0.48%
4,000
-1,330
-25% -$247K
1
2 3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q4 2018 Portfolio in Review

As of Q4 2018, Birchview Capital held 60 positions worth $106M, down 32% from $155M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Birchview Capital deployed $4.09M of net new capital in Q4 2018, opening 6 new positions and adding to 11 existing holdings. Its largest new stake was EQM Midstream Partners, LP: 50,000 shares worth $2.16M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Energy and Materials.

On the sell side, the largest reduction was ContraFect Corporation, an estimated $1.1M trimmed.

  • Birchview Capital's largest Q4 2018 buy was EQM Midstream Partners, LP: 50,000 shares worth $2.16M.
  • Birchview Capital added most to Celgene Corp in Q4 2018, an estimated $2.13M increase.
  • Birchview Capital's biggest Q4 2018 reduction was ContraFect Corporation, cutting an estimated $1.1M.
  • Birchview Capital fully exited AVEO Pharmaceuticals, Inc. in Q4 2018, selling an estimated $397K.
  • Birchview Capital's ten largest holdings make up 83% of its $106M portfolio in Q4 2018.
  • Birchview Capital opened 6 new positions and closed 8 in Q4 2018.
  • Birchview Capital's portfolio value fell 32% quarter-over-quarter to $106M.

Based on Birchview Capital's 13F filing for Q4 2018, filed 6 Feb 2019.